Gilead has said its possible coronavirus treatment has had positive results in a US study after it sustained a setback last week when an accidental early publication of results revealed a trial in China had been unsuccessful.
Shares in Gilead rallied 8 per cent in pre-market trading in New York after the company said it was aware of “positive data” from the study run by the US National Institutes of Allergy and Infectious Diseases. The NIAID did not respond to a request for comment.
“We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing,” Gilead said.
The company also released results from its own study, which appeared to show patients did just as well after a five day course of the drug than after 10 days. However, this study did not have a control arm comparing patients on remdesivir to patients who were not taking it and is not peer-reviewed.
Merdad Parsey, chief medical officer at Gilead, said that study “complements” the placebo controlled study by NIAID. If patients do not require a ten day course of the drug, “it could significantly expand the number of patients who could be treated with our current supply of remdesivir”, he said.
US stock futures rose on Wednesday ahead of the Wall Street open after the Gilead news was announced. Futures tracking the benchmark S&P 500 index were recently up 1.7 per cent, trading near their highs for the day.
https://news.google.com/__i/rss/rd/articles/CBMiP2h0dHBzOi8vd3d3LmZ0LmNvbS9jb250ZW50LzE2MjUyNzViLTk5ODEtNDlmNC1iNzg4LTY2MWY4MjQzODkwZNIBP2h0dHBzOi8vYW1wLmZ0LmNvbS9jb250ZW50LzE2MjUyNzViLTk5ODEtNDlmNC1iNzg4LTY2MWY4MjQzODkwZA?oc=5
2020-04-29 13:25:47Z
52780755087668
Tidak ada komentar:
Posting Komentar